Search Clinical Trials
589,087 trials
ID
Status
Phase
Title
Sponsor
NCT07644364
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Pressure and Patients With HypertensionNovartis PharmaceuticalsNot Yet RecruitingPhase 1
NCT07644364Not Yet Recruiting
Phase 1
HJB647 Phase 1b Study in Japanese Healthy Participants With Elevated Blood Press...Novartis Pharmaceuticals
NCT07645781
Cervical Stabilization Exercises IN Subacromial Impingement SyndromeCairo UniversityNot Yet RecruitingNot Applicable
NCT07645781Not Yet Recruiting
Not Applicable
Cervical Stabilization Exercises IN Subacromial Impingement SyndromeCairo University
NCT07644819
Preoperative Outreach to Improve Surgical AttendanceUniversity of California, San FranciscoNot Yet RecruitingNot Applicable
NCT07644819Not Yet Recruiting
Not Applicable
Preoperative Outreach to Improve Surgical AttendanceUniversity of California,...
NCT07645482
Frequency Rhythmic Electrical Modulated Stimulation Effect in Peripheral Neuropathy Patients Severity of Cases and Qol.Beni-Suef UniversityNot Yet RecruitingNot Applicable
NCT07645482Not Yet Recruiting
Not Applicable
Frequency Rhythmic Electrical Modulated Stimulation Effect in Peripheral Neuropa...Beni-Suef University
NCT07644286
A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofractionated Radiotherapy for Refractory pMMR/MSS Colorectal CancerTao ZhangRecruitingPhase 2
NCT07644286Recruiting
Phase 2
A Phase II Study of Pirfenidone Plus PD-1 Inhibitor With or Without Hypofraction...Tao Zhang
NCT07646548
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Berahyaluronidase Alfa and Dupilumab Without Berahyaluronidase Alfa in Healthy ParticipantsRegeneron PharmaceuticalsNot Yet RecruitingPhase 1
NCT07646548Not Yet Recruiting
Phase 1
Pharmacokinetics and Tolerability of Subcutaneous Dupilumab Coformulated With Be...Regeneron Pharmaceuticals
NCT07644039
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advanced MalignanciesPharmaMarRecruitingPhase 1
NCT07644039Recruiting
Phase 1
Study of PM54 in Combination With Immunotherapy in Adult Participants With Advan...PharmaMar
NCT07644052
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cannabis Use DisorderPleoPharma, Inc.RecruitingPhase 3
NCT07644052Recruiting
Phase 3
Efficacy of PP-01 in Mitigating Cannabis Withdrawal Symptoms in Adults With Cann...PleoPharma, Inc.
NCT07644351
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lymphoblastic Leukemia PatientsNovartis PharmaceuticalsCompleted
NCT07644351Completed
—
A Real-world Study of Asciminib Effectiveness in Philadelphia Positive Acute Lym...Novartis Pharmaceuticals
NCT07646236
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan Hospital-China Medical UniversityCompletedNot Applicable
NCT07646236Completed
Not Applicable
Gamification Versus E-Learning for Electrocardiogram EducationTaiwan Municipal An-Nan H...
NCT07643974
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research InstituteNot Yet RecruitingEarly Phase 1
NCT07643974Not Yet Recruiting
Early Phase 1
Coupled Gentamicin-Lactobacillus Rhamnosus in NLUTDMedstar Health Research I...
NCT07645768
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alternative to Conventional Posterior Double Plating in Extra-Articular Distal Shaft Humeral FracturesCairo UniversityActive Not RecruitingNot Applicable
NCT07645768Active Not Recruiting
Not Applicable
Is Anterior Reversed Proximal Humeral Locking Plate System (PHILOS) a Safe Alter...Cairo University
NCT07645443
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adults With Early PsychosisCentral Institute of Mental Health, MannheimRecruitingNot Applicable
NCT07645443Recruiting
Not Applicable
FEEL-GOOD: A Multicenter Trial of a Mindfulness-Based Group Therapy in Young Adu...Central Institute of Ment...
NCT07645014
Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polycystic Ovarian Syndrome.Riphah International UniversityRecruitingNot Applicable
NCT07645014Recruiting
Not Applicable
Comparative Effects of Neurodynamic Stretch and Myofascial Pain Release in Polyc...Riphah International Univ...
NCT07644559
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc.RecruitingPhase 2
NCT07644559Recruiting
Phase 2
A Phase 2 Study of VS-7375 in Patients With KRAS G12D-Mutated Pancreatic CancerVerastem, Inc.
NCT07644897
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced MelanomaSun Yat-sen UniversityRecruitingPhase 2
NCT07644897Recruiting
Phase 2
Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients...Sun Yat-sen University
NCT07644221
Feasibility and Effects of Noninvasive Brain Stimulation on Pain Perception in People With FibromyalgiaDepartment of Anesthesiology & Perioperative Medicine, University of PittsburghNot Yet RecruitingNot Applicable
NCT07644221Not Yet Recruiting
Not Applicable
Feasibility and Effects of Noninvasive Brain Stimulation on Pain Perception in P...Department of Anesthesiol...
NCT07645937
Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Morphology in Individuals With Relapsing-Remitting Multiple SclerosisDicle UniversityNot Yet RecruitingNot Applicable
NCT07645937Not Yet Recruiting
Not Applicable
Effects of Low-Load Blood Flow Restriction Exercise on Rectus Femoris Muscle Mor...Dicle University
NCT07645534
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta Pharm JSC, Russia) Compared With Ingavirin, Capsules, 90 mg, Under Fasting and Fed Conditions.Valenta Pharm JSCRecruitingPhase 1
NCT07645534Recruiting
Phase 1
Safety and Pharmacokinetics of Ingavirin Forte, Capsules, 90 mg + 20 mg (Valenta...Valenta Pharm JSC
Result Breakdown
Recruiting9 (45%)
Not yet recruiting8 (40%)
Completed2 (10%)
Active, not recruiting1 (5%)
not_applicable9 (45%)
Phase 24 (20%)
Phase 14 (20%)
Phase 31 (5%)
Not Specified1 (5%)
Early Phase 11 (5%)